Chronic myelogenous leukemia epidemiology and demographics: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) No edit summary |
||
Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Chronic myelogenous leukemia (CML) occurs in all age groups, but most commonly in the middle-aged and elderly. CML affects slightly more men than women. CML represents about 15–20% of all cases of adult leukemia in Western populations.<ref name="Faderl1990">{{cite journal|title=Chronic myelogenous leukemia: biology and therapy.|author=Faderl S, Talpaz M, Estrov Z, Kantarjian HM|journal=Annals of Internal Medicine|date=1999|volume=131|issue=3|pages=207-219|pmid=10428738}}</ref> In 2011, the age-adjusted [[incidence]] of CML was 1.81 per 100,000 persons in the United States.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | Chronic myelogenous leukemia (CML) occurs in all age groups, but most commonly in the middle-aged and elderly. CML affects slightly more men than women. CML represents about 15–20% of all cases of adult leukemia in Western populations.<ref name="Faderl1990">{{cite journal|title=Chronic myelogenous leukemia: biology and therapy.|author=Faderl S, Talpaz M, Estrov Z, Kantarjian HM|journal=Annals of Internal Medicine|date=1999|volume=131|issue=3|pages=207-219|pmid=10428738}}</ref> In 2011, the age-adjusted [[incidence]] of CML was 1.81 per 100,000 persons in the United States.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
==Epidemiology== | ==Epidemiology== |
Revision as of 18:23, 12 June 2014
Chronic myelogenous leukemia Microchapters |
Differentiating Chronic myelogenous leukemia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Chronic myelogenous leukemia epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Chronic myelogenous leukemia epidemiology and demographics |
FDA on Chronic myelogenous leukemia epidemiology and demographics |
CDC on Chronic myelogenous leukemia epidemiology and demographics |
Chronic myelogenous leukemia epidemiology and demographics in the news |
Blogs on Chronic myelogenous leukemia epidemiology and demographics |
Directions to Hospitals Treating Chronic myelogenous leukemia |
Risk calculators and risk factors for Chronic myelogenous leukemia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
Chronic myelogenous leukemia (CML) occurs in all age groups, but most commonly in the middle-aged and elderly. CML affects slightly more men than women. CML represents about 15–20% of all cases of adult leukemia in Western populations.[1] In 2011, the age-adjusted incidence of CML was 1.81 per 100,000 persons in the United States.[2]
Epidemiology
Incidence
Age
- While the overall age-adjusted incidence of CML in the United States between 2007 and 2011 is 1.7 per 100,000, the age-adjusted incidence of CML by age category is:[2]
- Under 65 years: 0.9 per 100,000
- 65 and over: 6.8 per 100,000
Gender
- In the United States, the age-adjusted incidence of CML by gender on 2011 is:[2]
- In males: 2.42 per 100,000 persons
- In females: 1.30 per 100,000 persons
- Shown below is an image depicting the observed incidence of myeloid leukemia by gender in the United States between 1975 and 2011. These graphs are adapted from SEER: The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.[2]
References
- ↑ Faderl S, Talpaz M, Estrov Z, Kantarjian HM (1999). "Chronic myelogenous leukemia: biology and therapy". Annals of Internal Medicine. 131 (3): 207–219. PMID 10428738.
- ↑ 2.0 2.1 2.2 2.3 2.4 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.